WCM
ACOR

Weld Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Weld Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-111
Closed -$103K – 1060
2019
Q2 		$103K Buy
+111
New +$136K 0.02% 693

Other funds holding ACOR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Weld Capital Management's ACOR Position: Q3 2019 in Review

Weld Capital Management sold out of Acorda Therapeutics (ACOR) in Q3 2019, closing a stake of 111 shares — an estimated $103K sold.

Weld Capital Management first reported a position in ACOR in Q2 2019 and held it in 1 quarter. The position peaked at $103K in Q2 2019. 151 funds tracked by Wall St. Rank hold ACOR as of Q3 2019.

  • Weld Capital Management reported no remaining Acorda Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Weld Capital Management sold 111 Acorda Therapeutics shares in Q3 2019, an estimated $103K.
  • Weld Capital Management first reported a position in Acorda Therapeutics in Q2 2019 and held it in 1 quarter.
  • Weld Capital Management's Acorda Therapeutics position peaked at $103K in Q2 2019.
  • 151 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2019.

Based on Weld Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.